Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QI ZHI WEI TONG granules for functional dyspepsia
ChiCTR1800014720Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Feb 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Qi Zhi Wei Tong granules and mosapride in functional dyspepsia (FD) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Symptom rating scale at week 6. Started Feb 2018; status: recruiting.
02
Drugs
Qi Zhi Wei Tong granulesmosapride
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on ChiCTR1800014720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014720.